XML 42 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6
Unaudited Quarterly Results (unaudited)
 12 Months Ended
Dec. 31, 2012
Unaudited Quarterly Results (unaudited) [Abstract]  
Unaudited Quarterly Results (unaudited)
14. Unaudited Quarterly Results (unaudited)

Summarized quarterly financial data during 2012 and 2011 are as follows:

 
 
2012 Quarter Ended
 
 
 
March 31
  
June 30
  
September 30
  
December 31
 
Revenues (1)
 
$
2,226
  
$
1,820
  
$
1,117
  
$
8,885
 
Net loss
  
(13,086
)
  
(10,720
)
  
(11,301
)
  
(324
)
Net loss per share - basic and diluted
  
(0.39
)
  
(0.32
)
  
(0.33
)
  
(0.01
)

 
 
2011 Quarter Ended
 
 
 
March 31
  
June 30
  
September 30
  
December 31
 
Revenues (2)
 
$
2,388
  
$
74,407
  
$
5,804
  
$
2,197
 
Net income (loss)
  
(22,927
)
  
55,486
   
(11,432
)
  
(10,746
)
Net income (loss) per share - basic
  
(0.69
)
  
1.66
   
(0.34
)
  
(0.32
)
Net income (loss) per share - diluted
  
(0.69
)
  
1.64
   
(0.34
)
  
(0.32
)
_______________

(1)
Revenues in the fourth quarter of 2012 include $5.0 million and $2.8 million from the MedImmune and CytoDyn Agreements, respectively.
(2)
Revenues in the second quarter of 2011 include $59.5 million from the Salix Agreement